Head and Neck Cancer Market: Global Industry Analysis and forecast 2029


Head and Neck Cancer Market is expected to reach US$ 3.18 Bn. at a CAGR of 15.23 during the forecast period 2029.

Head and Neck Cancer Market Drivers and Restrains:

Head & neck cancers contain a number of various malignant tumors that grow in or around the throat, larynx, nose, sinuses, lips, salivary glands, and mouth. The current standard of care for head and neck cancer includes surgery, radiation therapy, chemotherapy, and immunotherapy. Although traditional chemotherapeutic drugs first used in combination of radiation therapy, targeted immune therapies are developing as a standard treatment option for advanced-stage head & neck cancers.

Global Head and Neck Cancer MarketTo know about the Research Methodology :- Request Free Sample Report

Increase in the patient population, rise in health care infrastructure in developing economies, growth of the pharmaceutical industry, increase in product approvals, rise in government initiatives, surge in research and development activity are driving the head and neck cancer market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

Upsurge in consumption of alcohol and tobacco is a main cause of head and neck cancer. As per valued xx% of head and neck cancers is caused due to consumption of alcohol and tobacco. Increase in the number of head and neck cancer patients across the global is expected to drive demand for treatment. Recently, according to the American Society of Clinical Oncology (ASCO), head and neck cancer accounted for almost xx% of all cancers in the U.S. Furthermore, almost xx individuals will develop head and neck cancer in the upcoming period.

However, high failure rate of late stage clinical trials and high cost of treatment are restraining the head and neck market growth at global level. Increasing number of new product approvals in the head and neck cancer market is projected to provide lucrative opportunities during the forecast period.

Head and Neck Cancer Market Segmentation Analysis:

Based on the drug class, the head and neck cancer market has been segmented into EFGR inhibitors, Mitotic inhibitors and Anti-PD-a monoclonal antibodies. The anti-PD-1 monoclonal antibodies segment is expected to dominate the head and neck cancer market in 2018, owing to Increase in awareness, rise in demand for efficient drugs for treatment, and new product approvals are expected to drive the segment during the forecast period. Drug class such as anti-PD-1 monoclonal antibodies are regularly used in the treatment of head and neck (HNC) cancer. Such factors are expected to drive the segment during the forecast period like development of new products, rise in mergers & acquisitions, Increase in research and development activity in the pharmaceutical industry.

Based on the distribution channel, the head and neck market is classified into hospital pharmacies, drug stores & retail pharmacies, and online stores. The drug stores & retail pharmacies segment is dominated the market in 2018 owing to its higher presence. Furthermore, The online stores segment is expected to grow at the largest CAGR of xx% during the forecast period due to rise in preference for online purchasing of drugs over the traditional methods, increase in number of internet users, and growth in awareness about online pharmacy.

Head and Neck Cancer Market Regional Analysis:

Geographically, the head and neck cancer market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share of the head and neck cancer market in 2018 owing to increasing acceptance of advanced and high-cost drug therapies, increased treatment rate, and favorable reimbursement policies in the region.

Asia-Pacific offerings beneficial growth opportunities for the crucial players operating in the head & neck cancer market owing to large population base, surge in incidence of head & neck cancer, and increase in demand for head & neck cancer combination treatment. The growth in alcohol consumption, increase in cigarette smoking, and higher usage of tobacco are the risk factor, which are expected to fuel the market growth. In Asia Pacific region, Betel quid chewing is the most common form of tobacco chewing. Moreover, increase in awareness toward treatment & early screening of the disease and rise in healthcare expenditure fuel the growth of the market in this region. China and India are highly populated countries with the maximum number of head and neck cancer patients making them major contributor to the growth of the market in Asia Pacific.
A report cover the recent development for head and neck market i.e., Recently, Bristol-Myers Squibb Company declared the U.S. Food and Drug Administration (FDA) approval for Opdivo (nivolumab) injection for intravenous use in the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)

Head and Neck Cancer Market Competitive landscape

Major Key players operating in this market are AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Fortress Biotech, Inc., F. Hoffmann-La Roche Ltd. Manufacturers in the Head and Neck Cancer are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of head and neck cancer market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding head and neck cancer market dynamics, structure by analyzing the market segments, and project the head and neck cancer market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the head and neck cancer market make the report investor’s guide.

Scope of the Head and Neck Cancer Market: Inquire before buying






Global Head and Neck Cancer Market




Report Coverage
Details




Base Year:
2021
Forecast Period:
2022-2029




Historical Data:
2017 to 2021
Market Size in 2021:
US $ 1.02 Bn.




Forecast Period 2022 to 2029 CAGR:
15.23%
Market Size in 2029:
US $ 3.18 Bn.




 Segments Covered:
by Drug Class
• EFGR inhibitors
• Mitotic inhibitors
• Anti-PD-1 monoclonal antibodies




by Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Stores






Head and Neck Cancer Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Head and Neck Cancer Market Key Players are:

• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• Fortress Biotech, Inc.
• F. Hoffmann-La Roche Ltd.
• Immutep Limited
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Philips Healthcare
• GE Healthcare
• Siemens Healthcare
• Varian Medical Systems
• Shimadzu Corporation
• Addent, Inc.
• Identafi
• Velscope VX
• AB Science SA
• AbbVie Inc.
• Acceleron Pharma, Inc.
• ASAHI Roentgen
• Astellas Pharma Inc.

Frequently Asked questions

1. What is the market size of the Global Head and Neck Cancer Market  in 2021?
Ans. The market size Global Head and Neck Cancer Market t in 2021 was US$ 1.02 Billion.

2. What are the different segments of the Global Head and Neck Cancer Market ?
Ans. The Global Head and Neck Cancer Market  is divided into Drug Class and Distribution Channel.

3. What is the study period of this market?
Ans. The Global Head and Neck Cancer Markett will be studied from 2021 to 2029.

4. Which region is expected to hold the highest Global Head and Neck Cancer Market share?
Ans. The Asia Pacific dominates the market share in the  market.

5. What  is the Forecast Period of Global Head and Neck Cancer Market ?
Ans. The Forecast Period of the market is 2022-2029 in the market. 




Head and Neck Cancer Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources
3. Executive Summary: Global Head and Neck Cancer Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies
4.8. Patent Registration

5. Supply Side and Demand Side Indicators
6. Global Head and Neck Cancer Market Analysis and Forecast
6.1. Global Head and Neck Cancer Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Head and Neck Cancer Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Head and Neck Cancer Market Value Share Analysis, by Drug Class
7.4. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Drug Class
7.5. Global Head and Neck Cancer Market Analysis, by Drug Class
7.6. Global Head and Neck Cancer Market Attractiveness Analysis, by Drug Class

8. Global Head and Neck Cancer Market Analysis and Forecast, by Distribution Channel
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
8.4. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Distribution Channel
8.5. Global Head and Neck Cancer Market Analysis, by Distribution Channel
8.6. Global Head and Neck Cancer Market Attractiveness Analysis, by Distribution Channel

9. Global Head and Neck Cancer Market Analysis, by Region
9.1. Global Head and Neck Cancer Market Value Share Analysis, by Region
9.2. Global Head and Neck Cancer Market Size (US$ Bn) Forecast, by Region
9.3. Global Head and Neck Cancer Market Attractiveness Analysis, by Region

10. North America Head and Neck Cancer Market Analysis
10.1. Key Findings
10.2. North America Head and Neck Cancer Market Overview
10.3. North America Head and Neck Cancer Market Value Share Analysis, by Drug Class
10.4. North America Head and Neck Cancer Market Forecast, by Drug Class
10.4.1. EFGR inhibitors
10.4.2. Mitotic inhibitors
10.4.3. Anti-PD-1 monoclonal antibodies
10.5. North America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
10.6. North America Head and Neck Cancer Market Forecast, by Distribution Channel
10.6.1. Hospital Pharmacies
10.6.2. Drug Stores & Retail Pharmacies
10.6.3. Online Stores
10.7. North America Head and Neck Cancer Market Value Share Analysis, by Country
10.8. North America Head and Neck Cancer Market Forecast, by Country
10.8.1. U.S.
10.8.2. Canada
10.9. North America Head and Neck Cancer Market Analysis, by Country
10.10. U.S. Head and Neck Cancer Market Forecast, by Drug Class
10.10.1. EFGR inhibitors
10.10.2. Mitotic inhibitors
10.10.3. Anti-PD-1 monoclonal antibodies
10.11. U.S. Head and Neck Cancer Market Forecast, by Distribution Channel
10.11.1. Hospital Pharmacies
10.11.2. Drug Stores & Retail Pharmacies
10.11.3. Online Stores
10.12. Canada Head and Neck Cancer Market Forecast, by Drug Class
10.12.1. EFGR inhibitors
10.12.2. Mitotic inhibitors
10.12.3. Anti-PD-1 monoclonal antibodies
10.13. Canada Head and Neck Cancer Market Forecast, by Distribution Channel
10.13.1. Hospital Pharmacies
10.13.2. Drug Stores & Retail Pharmacies
10.13.3. Online Stores
10.14. North America Head and Neck Cancer Market Attractiveness Analysis
10.14.1. By Drug Class
10.14.2. By Distribution Channel
10.15. PEST Analysis
10.16. Key Trends
10.17. Key Development

11. Europe Head and Neck Cancer Market Analysis
11.1. Key Findings
11.2. Europe Head and Neck Cancer Market Overview
11.3. Europe Head and Neck Cancer Market Value Share Analysis, by Drug Class
11.4. Europe Head and Neck Cancer Market Forecast, by Drug Class
11.4.1. EFGR inhibitors
11.4.2. Mitotic inhibitors
11.4.3. Anti-PD-1 monoclonal antibodies
11.5. Europe Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
11.6. Europe Head and Neck Cancer Market Forecast, by Distribution Channel
11.6.1. Hospital Pharmacies
11.6.2. Drug Stores & Retail Pharmacies
11.6.3. Online Stores
11.7. Europe Head and Neck Cancer Market Value Share Analysis, by Country
11.8. Europe Head and Neck Cancer Market Forecast, by Country
11.8.1. Germany
11.8.2. U.K.
11.8.3. France
11.8.4. Italy
11.8.5. Spain
11.8.6. Rest of Europe
11.9. Europe Head and Neck Cancer Market Analysis, by Country
11.10. Germany Head and Neck Cancer Market Forecast, by Drug Class
11.10.1. EFGR inhibitors
11.10.2. Mitotic inhibitors
11.10.3. Anti-PD-1 monoclonal antibodies
11.11. Germany Head and Neck Cancer Market Forecast, by Distribution Channel
11.11.1. Hospital Pharmacies
11.11.2. Drug Stores & Retail Pharmacies
11.11.3. Online Stores
11.12. U.K. Head and Neck Cancer Market Forecast, by Drug Class
11.12.1. EFGR inhibitors
11.12.2. Mitotic inhibitors
11.12.3. Anti-PD-1 monoclonal antibodies
11.13. U.K. Head and Neck Cancer Market Forecast, by Distribution Channel
11.13.1. Hospital Pharmacies
11.13.2. Drug Stores & Retail Pharmacies
11.13.3. Online Stores
11.14. France Head and Neck Cancer Market Forecast, by Drug Class
11.14.1. EFGR inhibitors
11.14.2. Mitotic inhibitors
11.14.3. Anti-PD-1 monoclonal antibodies
11.15. France Head and Neck Cancer Market Forecast, by Distribution Channel
11.15.1. Hospital Pharmacies
11.15.2. Drug Stores & Retail Pharmacies
11.15.3. Online Stores
11.16. Italy Head and Neck Cancer Market Forecast, by Drug Class
11.16.1. EFGR inhibitors
11.16.2. Mitotic inhibitors
11.16.3. Anti-PD-1 monoclonal antibodies
11.17. Italy Head and Neck Cancer Market Forecast, by Distribution Channel
11.17.1. Hospital Pharmacies
11.17.2. Drug Stores & Retail Pharmacies
11.17.3. Online Stores
11.18. Spain Head and Neck Cancer Market Forecast, by Drug Class
11.18.1. EFGR inhibitors
11.18.2. Mitotic inhibitors
11.18.3. Anti-PD-1 monoclonal antibodies
11.19. Spain Head and Neck Cancer Market Forecast, by Distribution Channel
11.19.1. Hospital Pharmacies
11.19.2. Drug Stores & Retail Pharmacies
11.19.3. Online Stores
11.20. Rest of Europe Head and Neck Cancer Market Forecast, by Drug Class
11.20.1. EFGR inhibitors
11.20.2. Mitotic inhibitors
11.20.3. Anti-PD-1 monoclonal antibodies
11.21. Rest of Europe Head and Neck Cancer Market Forecast, by Distribution Channel
11.21.1. Hospital Pharmacies
11.21.2. Drug Stores & Retail Pharmacies
11.21.3. Online Stores
11.22. Europe Head and Neck Cancer Market Attractiveness Analysis
11.22.1. By Drug Class
11.22.2. By Distribution Channel
11.23. PEST Analysis
11.24. Key Trend
11.25. Key Development

12. Asia Pacific Head and Neck Cancer Market Analysis
12.1. Key Findings
12.2. Asia Pacific Head and Neck Cancer Market Overview
12.3. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Drug Class
12.4. Asia Pacific Head and Neck Cancer Market Forecast, by Drug Class
12.4.1. EFGR inhibitors
12.4.2. Mitotic inhibitors
12.4.3. Anti-PD-1 monoclonal antibodies
12.5. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
12.6. Asia Pacific Head and Neck Cancer Market Forecast, by Distribution Channel
12.6.1. Hospital Pharmacies
12.6.2. Drug Stores & Retail Pharmacies
12.6.3. Online Stores
12.7. Asia Pacific Head and Neck Cancer Market Value Share Analysis, by Country
12.8. Asia Pacific Head and Neck Cancer Market Forecast, by Country
12.8.1. China
12.8.2. India
12.8.3. Japan
12.8.4. ASEAN
12.8.5. Rest of Asia Pacific
12.9. Asia Pacific Head and Neck Cancer Market Analysis, by Country
12.10. China Head and Neck Cancer Market Forecast, by Drug Class
12.10.1. EFGR inhibitors
12.10.2. Mitotic inhibitors
12.10.3. Anti-PD-1 monoclonal antibodies
12.11. China Head and Neck Cancer Market Forecast, by Distribution Channel
12.11.1. Hospital Pharmacies
12.11.2. Drug Stores & Retail Pharmacies
12.11.3. Online Stores
12.12. India Head and Neck Cancer Market Forecast, by Drug Class
12.12.1. EFGR inhibitors
12.12.2. Mitotic inhibitors
12.12.3. Anti-PD-1 monoclonal antibodies
12.13. India Head and Neck Cancer Market Forecast, by Distribution Channel
12.13.1. Hospital Pharmacies
12.13.2. Drug Stores & Retail Pharmacies
12.13.3. Online Stores
12.14. Japan Head and Neck Cancer Market Forecast, by Drug Class
12.14.1. EFGR inhibitors
12.14.2. Mitotic inhibitors
12.14.3. Anti-PD-1 monoclonal antibodies
12.15. Japan Head and Neck Cancer Market Forecast, by Distribution Channel
12.15.1. Hospital Pharmacies
12.15.2. Drug Stores & Retail Pharmacies
12.15.3. Online Stores
12.16. ASEAN Head and Neck Cancer Market Forecast, by Drug Class
12.16.1. EFGR inhibitors
12.16.2. Mitotic inhibitors
12.16.3. Anti-PD-1 monoclonal antibodies
12.17. ASEAN Head and Neck Cancer Market Forecast, by Distribution Channel
12.17.1. Hospital Pharmacies
12.17.2. Drug Stores & Retail Pharmacies
12.17.3. Online Stores
12.18. Rest of Asia Pacific Head and Neck Cancer Market Forecast, by Drug Class
12.18.1. EFGR inhibitors
12.18.2. Mitotic inhibitors
12.18.3. Anti-PD-1 monoclonal antibodies
12.19. Rest of Asia Pacific Head and Neck Cancer Market Forecast, by Distribution Channel
12.19.1. Hospital Pharmacies
12.19.2. Drug Stores & Retail Pharmacies
12.19.3. Online Stores
12.20. Asia Pacific Head and Neck Cancer Market Attractiveness Analysis
12.20.1. By Drug Class
12.20.2. By Distribution Channel
12.21. PEST Analysis
12.22. Key Trend
12.23. Key Development

13. Middle East & Africa Head and Neck Cancer Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Head and Neck Cancer Market Overview
13.3. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Drug Class
13.4. Middle East & Africa Head and Neck Cancer Market Forecast, by Drug Class
13.4.1. EFGR inhibitors
13.4.2. Mitotic inhibitors
13.4.3. Anti-PD-1 monoclonal antibodies
13.5. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
13.6. Middle East & Africa Head and Neck Cancer Market Forecast, by Distribution Channel
13.6.1. Hospital Pharmacies
13.6.2. Drug Stores & Retail Pharmacies
13.6.3. Online Stores
13.7. Middle East & Africa Head and Neck Cancer Market Value Share Analysis, by Country
13.8. Middle East & Africa Head and Neck Cancer Market Forecast, by Country
13.8.1. GCC
13.8.2. South Africa
13.8.3. Rest of Middle East & Africa
13.9. Middle East & Africa Head and Neck Cancer Market Analysis, by Country
13.10. GCC Head and Neck Cancer Market Forecast, by Drug Class
13.10.1. EFGR inhibitors
13.10.2. Mitotic inhibitors
13.10.3. Anti-PD-1 monoclonal antibodies
13.11. GCC Head and Neck Cancer Market Forecast, by Distribution Channel
13.11.1. Hospital Pharmacies
13.11.2. Drug Stores & Retail Pharmacies
13.11.3. Online Stores
13.12. South Africa Head and Neck Cancer Market Forecast, by Drug Class
13.12.1. EFGR inhibitors
13.12.2. Mitotic inhibitors
13.12.3. Anti-PD-1 monoclonal antibodies
13.13. South Africa Head and Neck Cancer Market Forecast, by Distribution Channel
13.13.1. Hospital Pharmacies
13.13.2. Drug Stores & Retail Pharmacies
13.13.3. Online Stores
13.14. Rest of Middle East & Africa Head and Neck Cancer Market Forecast, by Drug Class
13.14.1. EFGR inhibitors
13.14.2. Mitotic inhibitors
13.14.3. Anti-PD-1 monoclonal antibodies
13.15. Rest of Middle East & Africa Head and Neck Cancer Market Forecast, by Distribution Channel
13.15.1. Hospital Pharmacies
13.15.2. Drug Stores & Retail Pharmacies
13.15.3. Online Stores
13.16. Middle East & Africa Head and Neck Cancer Market Attractiveness Analysis
13.16.1. By Drug Class
13.16.2. By Distribution Channel
13.17. PEST Analysis
13.18. Key Trend
13.19. Key Development

14. South America Head and Neck Cancer Market Analysis
14.1. Key Findings
14.2. South America Head and Neck Cancer Market Overview
14.3. South America Head and Neck Cancer Market Value Share Analysis, by Drug Class
14.4. South America Head and Neck Cancer Market Forecast, by Drug Class
14.4.1. EFGR inhibitors
14.4.2. Mitotic inhibitors
14.4.3. Anti-PD-1 monoclonal antibodies
14.5. South America Head and Neck Cancer Market Value Share Analysis, by Distribution Channel
14.6. South America Head and Neck Cancer Market Forecast, by Distribution Channel
14.6.1. Hospital Pharmacies
14.6.2. Drug Stores & Retail Pharmacies
14.6.3. Online Stores
14.7. South America Head and Neck Cancer Market Value Share Analysis, by Country
14.8. South America Head and Neck Cancer Market Forecast, by Country
14.8.1. Brazil
14.8.2. Mexico
14.8.3. Rest of South America
14.9. Brazil Head and Neck Cancer Market Forecast, by Drug Class
14.9.1. EFGR inhibitors
14.9.2. Mitotic inhibitors
14.9.3. Anti-PD-1 monoclonal antibodies
14.10. Brazil Head and Neck Cancer Market Forecast, by Distribution Channel
14.10.1. Hospital Pharmacies
14.10.2. Drug Stores & Retail Pharmacies
14.10.3. Online Stores
14.11. Mexico Head and Neck Cancer Market Forecast, by Drug Class
14.11.1. EFGR inhibitors
14.11.2. Mitotic inhibitors
14.11.3. Anti-PD-1 monoclonal antibodies
14.12. Mexico Head and Neck Cancer Market Forecast, by Distribution Channel
14.12.1. Hospital Pharmacies
14.12.2. Drug Stores & Retail Pharmacies
14.12.3. Online Stores
14.13. Rest of South America Head and Neck Cancer Market Forecast, by Drug Class
14.13.1. EFGR inhibitors
14.13.2. Mitotic inhibitors
14.13.3. Anti-PD-1 monoclonal antibodies
14.14. Rest of South America Head and Neck Cancer Market Forecast, by Distribution Channel
14.14.1. Hospital Pharmacies
14.14.2. Drug Stores & Retail Pharmacies
14.14.3. Online Stores
14.15. South America Head and Neck Cancer Market Attractiveness Analysis
14.15.1. By Drug Class
14.15.2. By Distribution Channel
14.16. PEST Analysis
14.17. Key Trend
14.18. Key Development

15. Company Profiles
15.1. Market Share Analysis, by Company
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Market Consolidation
15.2.3.1. M&A by Regions, Investment and Applications
15.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
15.3. Company Profiles: Key Players
15.3.1. AstraZeneca PLC
15.3.1.1. Company Overview
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. Business Strategy
15.3.1.5. Recent Developments
15.3.1.6. Company Footprint
15.3.2. Bristol-Myers Squibb Company
15.3.3. Eli Lilly and Company
15.3.4. Fortress Biotech, Inc.
15.3.5. F. Hoffmann-La Roche Ltd.
15.3.6. Immutep Limited,
15.3.7. Merck & Co., Inc.,
15.3.8. Merck KGaA
15.3.9. Novartis AG
15.3.10. Pfizer Inc.
15.3.11. Philips Healthcare
15.3.12. GE Healthcare
15.3.13. Siemens Healthcare
15.3.14. Varian Medical Systems
15.3.15. Shimadzu Corporation
15.3.16. Addent, Inc.
15.3.17. Identafi
15.3.18. Velscope VX
15.3.19. AB Science SA
15.3.20. AbbVie Inc.
15.3.21. Acceleron Pharma, Inc.
15.3.22. ASAHI Roentgen
15.3.23. Astellas Pharma Inc.

16. Primary Key Insights
  • INQUIRE BEFORE BUYING